Cabaletta Bio Net Income Over Time
| CABA Stock | USD 2.51 0.18 7.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cabaletta Bio Performance and Cabaletta Bio Correlation. Cabaletta | Build AI portfolio with Cabaletta Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. Projected growth potential of Cabaletta fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cabaletta Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Cabaletta Bio's market price often diverges from its book value, the accounting figure shown on Cabaletta's balance sheet. Smart investors calculate Cabaletta Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Cabaletta Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cabaletta Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cabaletta Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Cabaletta Bio and related stocks such as Editas Medicine, Allogene Therapeutics, and Capricor Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (13.7 M) | (72.9 M) | (97.2 M) | (120.3 M) | (110 M) | (133.7 M) | (109.4 M) | (185.1 M) | (204.4 M) | (153.2 M) | (237.1 M) | (213.4 M) | (202.7 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| CAPR | (200) | (4.9 M) | (1.9 M) | (8.9 M) | (6.2 M) | (12.9 M) | (18.8 M) | 2.4 M | (15.2 M) | (7.6 M) | (13.7 M) | (20 M) | (29 M) | (22.3 M) | (40.5 M) | (36.4 M) | (34.6 M) |
| KYTX | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (28.9 M) | (60.4 M) | (127.5 M) | (114.7 M) | (109 M) |
| LYEL | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (129.4 M) | (204.5 M) | (250.2 M) | (183.1 M) | (234.6 M) | (343 M) | (308.7 M) | (324.1 M) |
| AVIR | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (13.5 M) | (10.9 M) | 121.2 M | (115.9 M) | (136 M) | (168.4 M) | (151.5 M) | (144 M) |
| PRQR | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (12.1 M) | (20.8 M) | (39.1 M) | (43.6 M) | (36.9 M) | (56.7 M) | (46.6 M) | (60.7 M) | (64.4 M) | (28.1 M) | (27.8 M) | (25 M) | (26.2 M) |
| IMMP | (1.9 M) | (19.9 M) | (15.2 M) | (13.3 M) | (32.2 M) | (62 M) | (9.4 M) | (12.7 M) | (16.3 M) | (13.5 M) | (29.9 M) | (32.2 M) | (39.9 M) | (42.7 M) | (61.4 M) | (55.3 M) | (52.5 M) |
| LXEO | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (50.6 M) | (59.3 M) | (66.4 M) | (98.3 M) | (88.5 M) | (92.9 M) |
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
Cabaletta Bio and related stocks such as Editas Medicine, Allogene Therapeutics, and Capricor Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cabaletta Bio financial statement analysis. It represents the amount of money remaining after all of Cabaletta Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cabaletta Bio | CABA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2929 Arch Street, |
| Exchange | NASDAQ Exchange |
USD 2.51
Check out Cabaletta Bio Performance and Cabaletta Bio Correlation. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Cabaletta Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.